Chugai Pharma

4519 · TSE

Public Market Listing

4519TSE

TSE primary exchange listing

Live quotes, historical charts, and market capitalization for Chugai Pharma are available on Yahoo Finance.

View quote & market cap on Yahoo Finance ↗

External market data link · No third-party exchange redistribution

Assets

(14 total)
14Total Assets
10Approved
2Phase 3 / Filed
2Phase 1–2 / Early
24Diseases
Quick filter:
Showing 14 of 14 assets
Target & Modality
Alectinib(Alecensa)
Approved
ALKSmall molecule
Non-Small Cell Lung Cancer
Approved
PD-L1Monoclonal antibody
Non-Small Cell Lung CancerHepatocellular CarcinomaColorectal CancerBladder CancerSmall Cell Lung CancerMelanoma
Approved
MEK1/2 and RAF (CRAF, BRAF) · FAKSmall molecule
Ovarian Cancer
Approved
ROS1/NTRKSmall molecule
Non-Small Cell Lung Cancer
Approved
Angiopoietin-2 / VEGF-AMultispecific antibody
Age-Related Macular DegenerationDiabetic Macular Edema
Wet Age-Related Macular Degeneration
nemolizumab(Nemluvio)
Approved
IL-31 receptor AMonoclonal antibody
Atopic DermatitisPrurigo Nodularis
orforglipron(Foundayo)
Approved
GLP-1 receptorSmall molecule
ObesityType 2 DiabetesHypertensionAtherosclerotic Cardiovascular DiseaseOsteoarthritis
Rituximab(Rituxan)
Approved
CD20 · CD20-directed Cytolytic AntibodyMonoclonal antibody
Rheumatoid ArthritisDiffuse Large B-Cell LymphomaFollicular LymphomaChronic Lymphocytic Leukemia
sparsentan(Filspari)
Approved
Angiotensin II receptor type 1 (AT1R) + Endothelin receptor type A (ETA)Small molecule
Focal Segmental GlomerulosclerosisIgA Nephropathy
tocilizumab(Actemra / RoActemra)
Approved
IL-6 receptorMonoclonal antibody
Rheumatoid ArthritisCOVID-19
Phase 3
GLP-1 receptor · GLP-1/GIP receptor (dual)Peptide
ObesityType 2 Diabetes
Phase 3
Innate and adaptive immune activation (inactivated Streptococcus pyogenes)Bacterial immunotherapy
Bladder / Urothelial Cancer
Non-Muscle Invasive Bladder Cancer
Tofogliflozin(Apleway / Deberza)
Phase 2
SGLT2Small molecule
Type 2 Diabetes
Phase 1
ALKSmall molecule
Non-Small Cell Lung Cancer

Discontinued programmes (1)

Development of these assets stopped. Each page states the sourced discontinuation and keeps the trials as evidence history.

Upcoming events

(65 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (6)
November 2026 (2)
Atezolizumab + Alectinib · Alecensa + EntrectinibPhase 2Non-small Cell Lung Cancer
Est. primary completion 2026-11-30 · NCT04302025 · CT.gov ↗
What to watch
AtezolizumabPhase 3Cancer
Est. primary completion 2026-11-30 · NCT03148418 · CT.gov ↗
What to watch
December 2026 (4)
nemolizumab · NemluvioPhase 2Chronic Pruritus of Unknown Origin
Est. primary completion 2026-12 · NCT07074977 · CT.gov ↗
What to watch
TARA-002Phase 2Lymphatic Malformation
Est. primary completion 2026-12 · NCT05871970 · CT.gov ↗
What to watch
Est. primary completion 2026-12-01 · NCT03758989 · CT.gov ↗
What to watch
tocilizumab · Actemra / RoActemraPhase 1/2Lymphoma, Non-Hodgkin
Est. primary completion 2026-12-28 · NCT04077723 · CT.gov ↗
What to watch
2027 (26)
January 2027 (1)
Alectinib · Alecensa + EntrectinibPhase 3Non-Small Cell Lung Cancer
Est. primary completion 2027-01-19 · NCT05170204 · CT.gov ↗
What to watch
February 2027 (2)
orforglipron · FoundayoPhase 3Obesity, Overweight
Est. primary completion 2027-02 · NCT06672549 · CT.gov ↗
What to watch
tocilizumab · Actemra / RoActemraPhase 1/2Multiple Myeloma
Est. primary completion 2027-02-26 · NCT05535244 · CT.gov ↗
What to watch
March 2027 (2)
sparsentan · FilspariPhase 2Focal Segmental Glomerulosclerosis, Minimal Change Disease, Immunoglobulin A Nephropathy, IgA Vasculitis, Alport Syndrome
Est. primary completion 2027-03-12 · NCT05003986 · CT.gov ↗
What to watch
AtezolizumabPhase 3Breast Cancer
Est. primary completion 2027-03-31 · NCT04873362 · CT.gov ↗
What to watch
May 2027 (1)
orforglipron · FoundayoPhase 3Diabetes Mellitus, Type 2, Diabetes Melletus, Glucose Metabolism Disorders, Metabolic Disorders, Nutritional and Metabolic Diseases …
Est. primary completion 2027-05 · NCT07613307 · CT.gov ↗
What to watch
June 2027 (4)
EntrectinibPhase 1/2Solid Tumors, CNS Tumors
Est. primary completion 2027-06-30 · NCT02650401 · CT.gov ↗
What to watch
AtezolizumabPhase 2Neoplasm Metastasis
Est. primary completion 2027-06-30 · NCT00781612 · CT.gov ↗
What to watch
Atezolizumab + Alectinib · Alecensa + EntrectinibPhase 2/3Non-Small Cell Lung Cancer
Est. primary completion 2027-06-30 · NCT03178552 · CT.gov ↗
What to watch
AtezolizumabPhase 3Neoplasms
Est. primary completion 2027-06-30 · NCT05112965 · CT.gov ↗
What to watch
July 2027 (3)
Atezolizumab + tocilizumab · Actemra / RoActemraPhase 1/2Advanced Liver Cancers
Est. primary completion 2027-07-30 · NCT04524871 · CT.gov ↗
What to watch
AtezolizumabPhase 2Hepatocellular Carcinoma
Est. primary completion 2027-07-30 · NCT06096779 · CT.gov ↗
What to watch
Rituximab · RituxanPhase 2DLBCL, Lymphoma, B-Cell
Est. primary completion 2027-07-31 · NCT04594798 · CT.gov ↗
What to watch
August 2027 (5)
orforglipron · FoundayoPhase 3Obesity, Overweight
Est. primary completion 2027-08 · NCT06972459 · CT.gov ↗
What to watch
orforglipron · FoundayoPhase 3Obesity, Overweight, Type 2 Diabetes
Est. primary completion 2027-08 · NCT06972472 · CT.gov ↗
What to watch
orforglipron · FoundayoPhase 3Obesity, Overweight, Type 2 Diabetes
Est. primary completion 2027-08 · NCT06993792 · CT.gov ↗
What to watch
Avutometinib/defactinib (Avmapki Fakzynja Co-Pack)Phase 2Low Grade Ovarian Serous Adenocarcinoma, Ovarian Cancer
Est. primary completion 2027-08-01 · NCT07747506 · CT.gov ↗
What to watch
Est. primary completion 2027-08-31 · NCT06084936 · CT.gov ↗
What to watch
September 2027 (3)
orforglipron · FoundayoPhase 3Hypertension
Est. primary completion 2027-09 · NCT06948422 · CT.gov ↗
What to watch
orforglipron · FoundayoPhase 3Hypertension, Overweight or Obesity
Est. primary completion 2027-09 · NCT06948435 · CT.gov ↗
What to watch
orforglipron · FoundayoPhase 3Hypertension
Est. primary completion 2027-09 · NCT06952530 · CT.gov ↗
What to watch
October 2027 (3)
tocilizumab · Actemra / RoActemraPhase 2Non-Hodgkin Lymphoma
Est. primary completion 2027-10-01 · NCT05207670 · CT.gov ↗
What to watch
Rituximab · RituxanPhase 3Large B-Cell Lymphoma
Est. primary completion 2027-10-01 · NCT06047080 · CT.gov ↗
What to watch
nemolizumab · NemluvioPhase 3Atopic Dermatitis
Est. primary completion 2027-10-28 · NCT07762833 · CT.gov ↗
What to watch
November 2027 (1)
enicepatidePhase 2Obesity or Overweight
Est. primary completion 2027-11-12 · NCT07589686 · CT.gov ↗
What to watch
December 2027 (1)
orforglipron · FoundayoPhase 3Obesity, Overweight
Est. primary completion 2027-12 · NCT06672939 · CT.gov ↗
What to watch
2028 (16)
February 2028 (2)
enicepatidePhase 3Obesity, Overweight, Type 2 Diabetes Mellitus (T2DM)
Est. primary completion 2028-02-24 · NCT07670416 · CT.gov ↗
What to watch
AtezolizumabPhase 2Ovarian Cancer
Est. primary completion 2028-02-28 · NCT04931342 · CT.gov ↗
What to watch
March 2028 (3)
orforglipron · FoundayoPhase 3Obesity, Overweight
Est. primary completion 2028-03 · NCT07790861 · CT.gov ↗
What to watch
orforglipron · FoundayoPhase 3Urinary Incontinence,Stress
Est. primary completion 2028-03 · NCT07202884 · CT.gov ↗
What to watch
tocilizumab · Actemra / RoActemraPhase 3Diffuse Large B-cell Lymphoma
Est. primary completion 2028-03-31 · NCT04408638 · CT.gov ↗
What to watch
April 2028 (2)
orforglipron · FoundayoPhase 3Osteoarthritis
Est. primary completion 2028-04 · NCT07153471 · CT.gov ↗
What to watch
TARA-002Phase 3Bladder (Urothelial, Transitional Cell) Cancer, Non-Muscle Invasive Bladder Carcinoma …
Est. primary completion 2028-04 · NCT07480356 · CT.gov ↗
What to watch
May 2028 (1)
nemolizumab · NemluvioPhase 2Systemic Sclerosis
Est. primary completion 2028-05-28 · NCT07047690 · CT.gov ↗
What to watch
June 2028 (1)
orforglipron · FoundayoPhase 3Peripheral Arterial Disease
Est. primary completion 2028-06 · NCT07223593 · CT.gov ↗
What to watch
July 2028 (4)
Est. primary completion 2028-07-05 · NCT03768063 · CT.gov ↗
What to watch
nemolizumab · NemluvioPhase 2Moderate-to-Severe Atopic Dermatitis
Est. primary completion 2028-07-15 · NCT07660835 · CT.gov ↗
What to watch
enicepatidePhase 3Obesity or Overweight
Est. primary completion 2028-07-24 · NCT07351045 · CT.gov ↗
What to watch
tocilizumab · Actemra / RoActemraPhase 1/2Multiple Myeloma
Est. primary completion 2028-07-31 · NCT05583617 · CT.gov ↗
What to watch
August 2028 (1)
enicepatidePhase 3Obesity or Overweight, Type 2 Diabetes Mellitus
Est. primary completion 2028-08-07 · NCT07351058 · CT.gov ↗
What to watch
October 2028 (1)
Avutometinib/defactinib (Avmapki Fakzynja Co-Pack)Phase 3Low Grade Serous Ovarian Cancer
Est. primary completion 2028-10-15 · NCT06072781 · CT.gov ↗
What to watch
December 2028 (1)
Avutometinib/defactinib (Avmapki Fakzynja Co-Pack)Phase 1/2Pancreatic Ductal Adenocarcinoma, Non Small Cell Lung Cancer, Colorectal Cancer, Solid Tumor, Adult, G12D Mutated KRAS
Est. primary completion 2028-12 · NCT07020221 · CT.gov ↗
What to watch
2029 (7)
February 2029 (1)
AtezolizumabPhase 3Hepatocellular Carcinoma
Est. primary completion 2029-02-01 · NCT04712643 · CT.gov ↗
What to watch
March 2029 (1)
tocilizumab · Actemra / RoActemraPhase 1/2Non-Hodgkin's Lymphoma
Est. primary completion 2029-03-30 · NCT03075696 · CT.gov ↗
What to watch
April 2029 (2)
enicepatidePhase 3Type 2 Diabetes Mellitus
Est. primary completion 2029-04-02 · NCT07889648 · CT.gov ↗
What to watch
tocilizumab · Actemra / RoActemraPhase 2Multiple Myeloma
Est. primary completion 2029-04-13 · NCT07825064 · CT.gov ↗
What to watch
May 2029 (1)
AtezolizumabPhase 1/2Inoperable, Locally Advanced or Metastatic, ER-positive Breast Cancer
Est. primary completion 2029-05-30 · NCT04802759 · CT.gov ↗
What to watch
August 2029 (1)
orforglipron · FoundayoPhase 3Overweight, Prediabetic State, Prehypertension, Obesity, Abdominal
Est. primary completion 2029-08 · NCT07794579 · CT.gov ↗
What to watch
November 2029 (1)
Rituximab · Rituxan + tocilizumab · Actemra / RoActemraPhase 1/2Mature B-Cell Non-Hodgkin Lymphoma
Est. primary completion 2029-11-30 · NCT05533775 · CT.gov ↗
What to watch
2030 (3)
March 2030 (1)
orforglipron · FoundayoPhase 3Diabetes Mellitus, Type 2
Est. primary completion 2030-03 · NCT07668336 · CT.gov ↗
What to watch
September 2030 (2)
tocilizumab · Actemra / RoActemraPhase 1/2Follicular Lymphoma
Est. primary completion 2030-09-06 · NCT04246086 · CT.gov ↗
What to watch
Atezolizumab + tocilizumab · Actemra / RoActemraPhase 1/2Metastatic Breast Cancer
Est. primary completion 2030-09-30 · NCT03424005 · CT.gov ↗
What to watch
2031 (4)
January 2031 (1)
AtezolizumabPhase 2Adenocarcinoma, Pancreatic Ductal
Est. primary completion 2031-01-01 · NCT05968326 · CT.gov ↗
What to watch
March 2031 (1)
enicepatidePhase 3Overweight, Obesity, Cardiovascular Disease
Est. primary completion 2031-03-20 · NCT07918846 · CT.gov ↗
What to watch
August 2031 (1)
orforglipron · FoundayoPhase 3Atherosclerosis Cardiovascular Disease, Chronic Kidney Disease
Est. primary completion 2031-08 · NCT07241390 · CT.gov ↗
What to watch
October 2031 (1)
TARA-002Phase 2Non-muscle Invasive Bladder Cancer
Est. primary completion 2031-10 · NCT05951179 · CT.gov ↗
What to watch
2032 (2)
February 2032 (1)
Alectinib · AlecensaPhase 1/2ALK Fusion-positive Solid or CNS Tumors
Est. primary completion 2032-02-28 · NCT04774718 · CT.gov ↗
What to watch
September 2032 (1)
Est. primary completion 2032-09-25 · NCT04589845 · CT.gov ↗
What to watch
2033 (1)
March 2033 (1)
Atezolizumab + EntrectinibPhase 3Cancer
Est. primary completion 2033-03-01 · NCT05862285 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(13)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

9 October 2026ApprovalAtezolizumabFDA approves Tecentriq for adjuvant stage III dMMR colon cancer
US, FDA · Roche · Source ↗
22 September 2026Topline resultenicepatideCT-388-104 Phase 2 (NCT06628362) in type 2 diabetes met both primary endpoints (HbA1c and body weight)
Roche · Source ↗
17 June 2026Topline resultAvutometinib/defactinib (Avmapki Fakzynja Co-Pack)RAMP 205 updated results in first-line metastatic pancreatic cancer
14 April 2026ApprovalsparsentanFDA approves FILSPARI for FSGS
US, FDA · Source ↗
1 April 2026ApprovalorforglipronFDA approves Foundayo (orforglipron) for weight management
US, FDA · Source ↗
1 April 2026ApprovalorforglipronFDA Boxed Warning on Foundayo (NDA220934)
US, FDA · FDA · Source ↗
18 December 2025Topline resultorforglipronATTAIN-MAINTAIN: orforglipron met primary endpoint
Eli Lilly · Source ↗
7 October 2025FDA action dateAtezolizumabPDUFA date set for October 7, 2025
US, FDA · Source ↗
2 October 2025ApprovalAtezolizumabFDA approves Zepzelca plus atezolizumab as first-line maintenance for ES-SCLC
US, FDA · Source ↗
21 June 2025Topline resultorforglipronACHIEVE-1 Phase 3 detailed results published in NEJM
10 June 2025Filing acceptedAtezolizumabFDA accepts sNDA for Zepzelca plus atezolizumab
US, FDA · Source ↗
10 June 2025Priority reviewAtezolizumabFDA grants Priority Review
US, FDA · Source ↗

The 12 most recent of 13 past events are shown.

Financial reports

Annual history (2 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$8.4B$1.3B——report ↗
View 1 more year
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY$7.7B———report ↗